

NETT NewsFlash

November 2011



Enrollment Update:
As of 11-30-11 at 12p (EST)

ALIAS

ProTECT

point

<i>Arizona</i>	5	20	7
<i>Cincinnati</i>	28	45	23
<i>Emory</i>	24	41	10
<i>HFH</i>	11	7	22
<i>Kentucky</i>	28	13	18
<i>Maryland</i>	12	<5	11
<i>Minnesota</i>	19	31	17
<i>NYP</i>	25	<5	17
<i>OHSU</i>	48*	13	13
<i>Stanford</i>	19	34	17
<i>Temple</i>	25	23	15
<i>Texas</i>	30	41	14
<i>UCSF</i>	20	12	12
<i>UPenn</i>	33	26	49
<i>VCU</i>	10	9	6
<i>Wayne State</i>	24	7	42
<i>Wisconsin</i>	9	48	12
TOTAL	370	372	305

*OHSU WAS AN ORIGINAL SITE IN THE ALIAS I TRIAL AND CONTINUES IN THE ALIAS II TRIAL UNDER THE SAME CONTRACTUAL ARRANGEMENT WITH THE UNIVERSITY OF MIAMI STUDY CHAIR SITE.

POINT: Reminders

Enrollment: The NETT has reached the 300 subject mark! Thank you very much for your steadfast efforts on recruiting subjects to the study!

CRFs: The POINT CRFs include questions about premature study drug termination. If a subject discontinues the study drug, he/she has not necessarily ended the study. The subject may be willing to be followed through 90 days, especially due to the limited follow-up for this trial. It is important that we differentiate between premature study drug and premature study termination and not classify subjects as withdrawing consent when they are willing to continue.

Prohibited and Discouraged Medications: Please continue to provide frequent reminders to the clinical teams and subjects to avoid concomitant use of prohibited/discouraged medications while on study drug.

NETT Network

Contact Us: nett-contact@umich.edu (734) 232-2142 Website: <http://nett.umich.edu>